Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
HCW Biologics Inc. Market Cap
The HCW Biologics Inc. (HCWB) share price is expected to increase by 391.8% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered HCWB. Price targets range from $3 at the low end to $3 at the high end. The current analyst consensus for HCWB is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
HCWB is a stock in Health Care which has been forecasted to be worth $3 as an average. On the higher end, the forecast price is $3 USD by from and on the lower end HCWB is forecasted to be $3 by from .
These are the latest 20 analyst ratings of HCWB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Tony Butler EF Hutton | Buy | $9 | Assumes | Jun 1, 2023 |
| Constantine Davides EF Hutton | Buy | $9 | Reiterates | Apr 19, 2023 |
| Constantine Davides EF Hutton | Buy | $9 | Reiterates | Mar 30, 2023 |
| Constantine Davides EF Hutton | Buy | $9 | Reiterates | Mar 23, 2023 |
| Soumit Roy JonesTrading | Buy | $8 | Initiates | Nov 8, 2022 |
| Michael Okunewitch Maxim Group | Buy | $4 | Initiates | Mar 24, 2022 |
EF Hutton | Buy | Initiates | Nov 19, 2021 |
When did it IPO
2021
Staff Count
45
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Hing C. Wong Ph.D.
Market Cap
$17.8M
In 2023, HCWB generated $2.8M in revenue, which was a decrease of -57.72% from the previous year. This can be seen as a signal that HCWB's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 01 Nov 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the u201cCompanyu201d or u201cHCW Biologicsu201d) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (u201cSITCu201d) from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota.
Wed, 06 Sep 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months
Fri, 11 Aug 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the u201cCompanyu201d or u201cHCW Biologicsu201d) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023.
Wed, 14 Jun 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent Cells in Subjects with Cancer Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent Cells in Subjects with Cancer
Tue, 09 May 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MIRAMAR, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the u201cCompanyu201d or u201cHCW Biologicsu201d) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2023.
Thu, 27 Apr 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the u201cCompanyu201d or u201cHCW Biologicsu201d) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, entered into a $26.25 million development line of credit agreement on April 21, 2023.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
